Pluristem Therapeutics - PLUR Net Assets per Single Share

Graphic logo of Pluri (PLUR)

The development of cellular products by Pluri Inc. (PLUR) relies on clinical trial results and strict cost control. This chart of the stock's historical book value confirms current stability, with the value fixed at -2.15. Stability is ensured by bioengineers creating unique therapy methods, as well as compliance with environmental standards and bioethics during bioreactor production.

Pluri Inc (PLUR): Share Book Value from 04/28/2023 to 10/27/2026

Pluristem Therapeutics - analytical breakdowns and key metrics (PLUR)

- price and consensus price forecast:
Stock Quotes Pluri Inc|PLUR - Analyst Consensus Forecast
- market capitalization data:
Market Value Pluri Inc.|PLUR - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share Pluri|PLUR - Net Asset Value|Market Capitalization to Book Value Ratio pluri-biotech.com|PLUR - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Pluri Inc.|PLUR - Long-Term Debt to Capital|Short-Term Debt to Equity Pluri Inc|PLUR - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Pluri Inc.
Fundamental company valuation:pluri-biotech.com - PLUR
Manufactured products of Pluri Inc

Calculating net asset value per share, which determines the real value of capital minus liabilities, is critical for selecting assets with a high margin of safety. Analyzing this metric via the historical book value per share chart from GURU.Markets allows for an assessment of how the capitalization of biomedical complexes and the readiness of Pluri Inc. (PLUR) production facilities translate into fundamental shareholder value.

Competitors of Pluri Inc. (PLUR)

Ascendis Pharma Inc. - Accounting Value per Share|MDGL: Book Value per Share|Net Assets per Single Share Corcept Therapeutics CORT|RYTM (rhythmtx.com) - Accounting Value of a Share|Net Assets per Single Share Akero AKRO|Share Book Value Metsera, Inc.|MoonLake Pharma (MLTX) - Book Value per Share|Accounting Value of a Share Crinetics Corp (CRNX)|Book Value per Share NAMS (NewAmsterdam Pharma)|soleno.life - Book Value per Share|Net Assets per Single Share Amicus Therapeutics, Inc. (FOLD)|ETNB: Accounting Value of a Share|AGIO (Agios Pharmaceuticals Inc) - Net Assets per Single Share|Structure Corp (GPCR) - Accounting Value per Share|MDXG (MiMedx Group, Inc.) - Book Value per Share|Book Value per Share rezolutebio.com (RZLT)|Lexicon Pharmaceuticals, Inc. (LXRX) - Accounting Value per Share|Accounting Value of a Share MBX (MBX Biosciences, Inc.)|Altimmune Corp - Net Assets per Single Share|Accounting Value per Share Aardvark Pharma AARD|SGMT (Sagimet Biosciences) - Book Value per Share|bioagelabs.com (BIOA) - Net Asset Value per Share|BMEA - Accounting Value per Share|Quince Therapeutics, Inc. (QNCX) - Book Price of a Share|GUTS (Fractyl) - Book Value per Share|Book Value per Share vTv Therapeutics Inc|Book Value per Share Agape ATP Corporation (ATPC)|Net Assets per Single Share SYBX (synlogictx.com)|LPCN: Net Assets per Single Share|Matinas BioPharma Holdings, Inc. - Net Asset Value per Share|SPRB - Net Assets per Single Share|GLTO - Net Assets per Single Share|Carmell Corporation - Book Value per Share|LUMO (lumos-pharma.com) - Net Assets per Share|ONVO: Net Assets per Single Share|Net Assets per Share RDUS